Compare YSWY & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSWY | XERS |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | 435 |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2026 | 2021 |
| Metric | YSWY | XERS |
|---|---|---|
| Price | $20.75 | $8.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 268.9K | ★ 1.7M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | N/A | $22.86 |
| P/E Ratio | ★ N/A | $842.50 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $18.92 | $5.25 |
| 52 Week High | $21.90 | $10.08 |
| Indicator | YSWY | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 48.82 |
| Support Level | $19.25 | $8.00 |
| Resistance Level | $21.38 | $8.42 |
| Average True Range (ATR) | 1.12 | 0.32 |
| MACD | 0.10 | -0.11 |
| Stochastic Oscillator | 76.07 | 6.93 |
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.